x

Posted 21 March, 2024

Evoke Pharma Inc appointed Matthew J. D'Onofrio as new CEO

Nasdaq:EVOK appointed new Chief Executive Officer Matthew J. D'Onofrio in a 8-K filed on 21 March, 2024.


  On March 20, 2024, the board of directors (the "Board') of Evoke Pharma, Inc. (the "Company") appointed Matthew J. D'Onofrio as the Company's Chief Executive Officer, effective as of March 31, 2024.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Evoke Pharma Inc
Health Care/Life Sciences • Pharmaceuticals
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It also develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.
Market Cap
$5.64M
View Company Details
Evoke Pharma Inc by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On March 20, 2024, the board of directors (the "Board') of Evoke Pharma, Inc. (the "Company") appointed Matthew J. D'Onofrio as the Company's Chief Executive Officer, effective as of March 31, 2024. Mr. D'Onofrio will succeed Dave A. Gonyer, R. Ph., the Company's current Chief Executive Officer, who is resigning effective as of March 31, 2024, for personal reasons. Mr. Gonyer's departure is not due to any disagreement with the Company or on any matter related to the Company's operations, policies, or practices. Mr. Gonyer has also resigned as a member of the Board and Mr. D'Onofrio was appointed as a member of the Board, in each case, effective as of March 31, 2024. 


Mr. D'Onofrio is one the Company's co-founders and has served as our President, Chief Operating Officer, Secretary and Treasurer since February 2023 and in prior executive positions at the Company since March 2007. The full biography and other information with respect to Mr. D'Onofrio required by Item 5.02(c) of Form 8-K are included in the Company's proxy statement on Schedule 14A for the 2023 annual meeting of stockholders filed with the SEC on March 29, 2023 under the heading "Executive Compensation and Other Information" and such biography and information are incorporated herein by reference. There are no family relationships between Mr. D'Onofrio and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.